Malignant endocrine tumors in childhood and adolescence

Interventions: Group 1: Patients with a malignant disease are initially reported to the German Childhood Cancer Registry (DKKR) by the pediatric oncology centers treating them. This generates a PatID (patient identifier) ??and a MaligID (malignant identifier). If there is a malignant endocrine tumor that is recorded in our registry, the DKKR sends a notification form with these two IDs to the MET registry center. The registry center then contacts the reporting pediatric oncology department and sends the patient information and declarations of consent.
The treating physicians initially check the existence of inclusion and exclusion criteria. Insofar as inclusion criteria are met but exclusion criteria are not present, there is detailed medical information and written information about the content, risks and benefits of the MET registry. If the patient and the legal guardian agree, the patient can be included in the MET registry. In some cases, pediatric oncology centers contact the MET Help Desk for clinical advice. Patient data in German-speaking countries is recorded via the GPOH platform MARVIN (XClinical) in so-called electronic Case Report Forms” (eCRFs).
The patient information and declarations of consent are then sent in this way.
Primary outcome(s): The primary objectives of the MET Registry include:
1. The prospective registration of all children and adolescents with an initial diagnosis of a malignant endocrine tumor between the ages of 0 and 18 years
2. The scientific evaluation with the aim of optimizing the therapy of affected patients
Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis